Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (November 2020)
34 slides from Genprex's investor presentation, Nov 16, 2020
Slide 1: Reprogramming the Course of Cancer and Diabetes
© Genprex REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX November 2020
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘Statements contained in this presentation regarding matters that are not historical facts are “forward-lookingstatements" within the meaning of the Private Securities Litigation Reform Actof 1995. Because such statements are subjectto risks and uncertainties, actual resul
Slide 3: GNPX at a Glance
GNPX AT A GLANCE 10-DAY AVG SHARES COMPANY SYMBOL EXCHANGE | SHAREPRICE | MARKET CAP ne Gureunas Genprex, Inc. GNPX Nasdaq $3.16 $125M 569K 39,618,722 $21,058,386 All data is as of November 12, 2020 except for outstanding shares which is as of November 6, 2020 and cash which is as of September 30, 2
Slide 4: Major Competitive Advantages
MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM. Our non-viral Oncoprex® nanoparticle delivery system is designed to deliver a variety of therapeutic genes to fightcancer. Data indicate ‘that our lead drug candidate, REQORSA™ immunogene therapydrug, may be combined witha number of approvedcancer
Slide 5: Executive Summary
EXECUTIVE SUMMARY GENE THERAPY PLATFORM FIRST SYSTEMIC GENE THERAPY USED FOR CANCER IN HUMANS LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING CANCER DRUGS FDA FAST TRACK DESIGNATION MAJOR COMPETITIVE ADVANTAGES, DEMONSTRATED CLINICAL ACHIEVEMENT INITIATING TWO LUNG CANCER TRIALS IN
Slide 6: Fast Track Designation
FAST TRACK DESIGNATION ~ * we Genprex received Fast Track Designation (FTO) for REQORSA + AstraZeneca’s Tagrisso for non-small cell lung cancer (NSCLO) patients that progressed on Tagrisso. Tagrisso had $3B+ worldwide gross sales in 2019, and itis Astrazeneca’s highest grossing product. FTD is for t
Slide 7: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE ‘CLINICAL CLINICAL CLINICAL Fpecenacet PHASE PHASE 2 PHASES ‘ONCOLOGY REQORSA™ + TARGETED THERAPIES Acclaim 1 ca once: REQORSA™ + IMMUNOTHERAPIES ee DIABETES a © Genprex * Nasdaq: GNPX
Slide 8: Acclaim-1
lis: Acclaim -1 GENERAL STUDY CHARACTERISTICS + REQORSA in combination with AstraZeneca's Tagrisso for NSCLC + Patients with Stage 4, EGFR mutant NSCLC whose disease progressed after Tagrisso + ~10 US. sites + ~100 patients Phase 1:9-18 patients Phase 2: 82 patients + Interim analysis at 53 events (
Slide 9: Phase 1 and Phase 2 Study Design and Endpoints
oF wz 2O fa PHASE 2 COMPONENT 343 dose escalation of REQORSA in combination with Tagrisso Randomized 1:1, open-label, 2arm study of REQORSA in combination with Tagrisso vs, Tagrisso monotherapy PRIMARY ENDPOINT + Dose limiting toxicity PRIMARY ENDPOINT + Progression free survival (PFS) + PFS improve
Slide 10: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES * Genprex’s oncology combination treatment © Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes. immunotherapies. May eliminate daily burden of ch
Slide 11: Oncology Program
Slide 12: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS A% 3B+ MOST COMMON LUNG CANCER TAGRISSO® 2019 SALES NSCLC represents the majority of all lung cancers. AstraZeneca’s highest grossing product. 11B+ WORLDWIDE CASES KEYTRUDA® 2019 SALES Almost two million cases per year worldwide. Merck's highest grossing
Slide 13: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM GENES Multiple tumor suppressor genes SYNERGIES Modern approach using combination therapy CANCERS Genetic mutations found in other cancers Genprex NasdagscNex >
Slide 14: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Positively charged TUSC2 gene nanoparticle | Cassette S) (S) om > —_— — le (S) Nanoparticle attaches Cancer killing genes Cell death to cancer cell integrate into cell Negatively charged cancer cell Our non-vira
Slide 15: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN IDEAL MEANS TO SELECTIVELY TARGET CANCER CELLS + The activities of glucose metabolism have a profound impact on the surface of cancer cells, + Elevated glycolysis in cancer cells lead to a higher secretion of lactate Secreted lactate ions remove
Slide 16: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 —a z a8 mS oe CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Genpre Nasdaq: GNPX
Slide 17: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Nasdaq: GNPX
Slide 18: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM = CcrvorPembrorrusc2 A Active T cells (Lung) Pon In Lung Metastasis. NK in Lung Metastasis = 19- 20 Fy ¥ 2 E;, Sm. ae 3 : g Gao Be 3s. i = Er Immunomodulation of Carbo + Pembro + °. . £ TUSC2 demonstrates rationale for the pater irs as Pi Acclaim-1 and Acclaim-2 c
Slide 19: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Maximum Tolerated
Slide 20: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGFR STATUS RESPONSE PRIOR THERAPY eee Positive (exon 18420) Complete Response chemo Negative 24% regression Target Lesion Chemo /anti-PD1 a 30% regression one Target Lesion Negative 18% regress
Slide 21: REQORSA + Tarceva Combination: Best Response
EGFR status/mutation REQORSA + TARCEVA COMBINATION s\ mer Plot of Best Response, with Time on Study Negative 4 Negative 4 Positive (exon 18+20) 4 Negative 4 Negative 4 Negative 4 Negative 4 Negative 4 sD Positive (exon 21) 4 a@uadiccey Neestie'-7 aa 4 Chemotherapy+Immunotherapy Negative 4 sD Bae Pos
Slide 22: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER ‘Survival on Lung Metastasis Model Non-treated TUsce-treated 100 me powers is = = Tusce 2 == tusc2-o+ i a == tuscarrorscttas & od 10 6 Ey zs Days TUSC2+anti-PD1 exhibit greater a
Slide 23: REQORSA Shows Synergy with Immunotherapies (Humanized Mouse Model)
Strong antitumor immune responses of anti-PD1 were REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda found against PDX tumors developed in humanized mice. see Sao Poms seam, REQORSA + Keytruda + Chemo REQORSAta
Slide 24: nS ae wi ov <2 Oa
nS ae wi ov <2 Oa
Slide 25: Diabetic Patients in Need of Modern Therapy
DIABETIC PATIENTS IN NEED OF MODERN THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S', or 10 percent of the U.S. population. May replace daily burden of blood glucose monitoring and insulin replacement th
Slide 26: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION AAV vector to deliver the Pdx1 and MafAgenes to the pancreas. S Novel infusion process uses an endoscope and an Intraductal infusion of Pic and Mofo: Transforms alpha cells in the pancreas into cpresing AAV ry functional bet
Slide 27: Key Milestones & Activities Through Early 2021
KEY MILESTONES & ACTIVITIES THROUGH EARLY 2021 a MANUFACTURING ‘ CLINICAL Continue preparations for combination Clinical trials of REQORSA with Tagr and Keytruda, respectively, while Complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion planning to i
Slide 28: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS , ; DRUG COMPANY SYMBOL EXCHANGE INDICATION aesy| GIGS VALUATION noe Melanoma, Head and Neck, CareokNSetC Chane’ Ufleucel NS Phasesti2) 8.4 ee fig Selec Wirge'Theapeutis MTX nasdaq NSCLE,COIFECELEMA wrysye seavatrib Phase32) «S118 ape Eninosta Arai, i naséeq
Slide 29: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD CATHERINE VACZY Chairman, President & Chief Executive Officer Executive VP, General Counsel & Chief Strategy Officer + 20+ years of expertisein corporate law, including corporate governance, in biotech industry + 20+ years of experiencein senior exe
Slide 30: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing + 20+ years of expertise in biotech IP law, business development, licensing transactions + Seasoned IP executive and attorney SHANNON INMAN Vice President of Global Clinical Operations +
Slide 31: Meet Our Team: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD PASI ANTERO JANNE MD, PhD + Professor of Medicine, Harvard Medical School: Director of Dana Farber Cancerlnstitute Lowe Center for Thoracic Oncology; Scientific Director of the Belfer Centerfor Applied Cancer Science JACK A. ROTH MD, FACS, Chairman Professor a
Slide 32: Meet Our Team: Board of Directors
Coming Soon MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board MN BRENT LONGNECKER Board Director + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm +: Chief ene ornten!leneriee tens eer
Slide 33: 21st Century Gene Therapies
21ST CENTURY GENE THERAPIES MARKET GAPS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS SCALING UP MANUFACTURING PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS Nasdaq: GNPX
Slide 34: Genprex Contact
oO Genprex’ NASDAQ: GNPX 1601 Trinity St, Bldg B, #3.312.09, Austin, Texas 78712 (877)774-GNPX | investors@genprex.com Nasdaq: GNPX